Abstract
Although most antidepressants suppress serotonin (5-HT) and/or noradrenaline reuptake, blockade of 5-HT2C receptors and α2-adrenoceptors likewise enhances monoaminergic transmission. These sites are targeted by the urea derivative N- [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo[e]indole-3-carboxamide (S32212). S32212 was devoid of affinity for monoamine reuptake sites, yet displayed pronounced affinity (pKi, 8.2) for constitutively active human 5-HT2CINI (h5-HT2CINI) receptors, behaving as an inverse agonist in reducing basal Gαq activation, [3H]inositol-phosphate production, and the spontaneous association of h5-HT2CINI-Renilla luciferase receptors with β-arrestin2-yellow fluorescent protein. Furthermore, upon 18-h pretreatment, S32212 enhanced the plasma membrane expression of h5-HT2CINI receptors as visualized by confocal microscopy and quantified by enzyme-linked immunosorbent assay. Its actions were prevented by the neutral antagonist 6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]indoline-1-carboxamide (SB242,084), which also impeded the induction by long-term exposure to S32212 of otherwise absent Ca2+ mobilization in mouse cortical neurones. In vivo, S32212 blunted the inhibitory influence of the 5-HT2C agonist 2-(3-chlorobenzyloxy)-6-(1-piperazinyl)pyrazine (CP809,101) on ventrotegmental dopaminergic neurones. S32212 also blocked 5-HT-induced Gαq and phospholipase C activation at the h5-HT2A and, less potently, h5-HT2B receptors and suppressed the discriminative stimulus properties of the 5-HT2A agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane in rats. S32212 manifested marked affinity for human α2A- (pKi 7.2), α2B- (pKi 8.2), and α2C- (pKi 7.4) adrenoceptors, at which it abolished noradrenaline-induced recruitment of Gαi3, Gαo, adenylyl cyclase, and extracellular-regulated kinase1/2. Moreover, S32212 dose-dependently abolished the discriminative stimulus effects of the α2-adrenoceptor agonist (S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4,2′-(1′,2′,3′,4′-tetrahydronaphthalene)] (S18616). Finally, S32212 displayed negligible affinity for α1A-adrenoceptors, histamine H1 receptors, and muscarinic M1 receptors. In conclusion, S32212 behaves as an inverse agonist at h5-HT2C receptors and as an antagonist at human α2-adrenoceptors (and h5-HT2A receptors). Its promising profile in preclinical models potentially relevant to the treatment of depression is described in J Pharmacol Exp Ther 340:765–780, 2012.
Footnotes
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
ABBREVIATIONS:
- MT
- melatonin
- 5-HT
- serotonin
- h5-HT
- human 5-HT
- 5-HTP
- 5-hydroxytryptophan
- AR
- adrenoceptor
- h-AR
- human AR
- CHO
- Chinese hamster ovary
- HEK
- human embryonic kidney
- DOI
- 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
- ERK
- extracellular-regulated kinase
- [35S]GTPγS
- guanosine-5′-O-(3-[35S]thio)-triphosphate
- IP
- inositol phosphate
- NA
- noradrenaline
- PI
- phosphatidyl inositol
- PLC
- phospholipase C
- SPA
- scintillation proximity assay
- LiCl
- lithium chloride
- VTA
- ventral tegmental area
- YFP
- yellow fluorescent protein
- ANOVA
- analysis of variance
- ELISA
- enzyme-linked immunosorbent assay
- Rluc
- Renilla luciferase
- BRET
- bioluminescence resonance energy transfer
- PBS
- phosphate-buffered saline
- BSA
- bovine serum albumin
- S32212
- N- [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo[e]indole-3-carboxamide
- SB242,084
- 6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]indoline-1-carboxamide
- S18616
- (S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4, 2′-(1′,2′,3′,4′-tetrahydronaphthalene)]
- CP809,101
- 2-(3-chlorobenzyloxy)-6-(1-piperazinyl)pyrazine
- RX821,002
- {2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline}
- WAY100,635
- N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridinyl-trihydrochloride
- GR125,743
- N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-4-(4-pyridyl)benzamide
- BRL43,694
- N-(9-methyl-9-azabicyclo[3.3.1.]non-3-yl-1-methyl-1H-indazol-3-carboxamide
- GR113,808
- 1-methyl-1H-indole-3-carboxylic acid 1-[2-(methylsulfonamido)ethyl]piperidin-4-ylmethyl ester
- LSD
- d-lysergic acid diethylamide
- CGP12177
- 4-[3-[(1,1-dimethylethyl)amino]2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one
- SCH23390
- (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
- GBR12935
- 1-(2-diphenylmethoxyethyl)-4-(3-phenylpropyl)piperazine
- Ro41-1049
- N-(2-aminoethyl)-5-(3-fluorophenyl)-4-thiazolecarboxamide
- Ro19-6327
- N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
- AFDX384
- N-[2-[2-[(dipropylamino)methyl]-1-piperidinyl]ethyl]-5,6-dihydro-6-oxo-11H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide.
- Received September 30, 2011.
- Accepted November 29, 2011.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|